Phase-II data show reduced hepatitis-C RNA levels among HIV-positive patients, the drugmaker shared at a medical meeting. Boehringer also released co-infection data.
The drugmaker announced Tuesday that it will pursue a Phase-III Yervoy-nivolumab study.
Roche said an onartuzumab and Tarceva mix did not help advanced non-small cell lung cancer patients with MET-positive tumors.
The drugmaker said JAK inhibitor GSK2586184 showed no effect in Phase II and has put an ulcerative colitis test on hold.
The drugmaker says researchers will be able to view patient-level data and promises less jargon-filled summaries by year-end.
Phase-III results, top-lined today, show Lilly's investigational GLP-1 drug is well-positioned to eat into the multi-billion-dollar diabetes market now dominated by Novo Nordisk.
The drugmaker was scant on details, but Phase-III ramucirumab results among non-small cell lung cancer patients showed increased overall and progression-free survival vs. placebo.
TapTrak seeks to apply behavioral tracking to clinical trials.
A sealed complaint, reported on by the Wall Street Journal, builds on concerns that were already surrounding the now-controversial Plato study.
The school will act as an independent panel for the drug maker, reviewing requests from investigators for access to anonymized, clinical-trial data.
A clinical trial shows that using Xtandi before chemotherapy—Zytiga's indication—improves progression-free survival.
The US agency says we've got too much data that cannot be reproduced.
Additional studies of bitoperin, which is meant to target the condition's negative symptoms, are ongoing.
Merck and Celgene are exploring a combination that could solidify their immuno-oncology footholds.
Mid-stage data show the drug, romosozumab, was associated with significant increases in bone mineral density compared to Lilly's Forteo and off-patent Fosamax.
The American College of Cardiology is contributing its Pinnacle registry to identify clinical trial patients.
A recent poll shows a strong desire among web-savvy patients to play a more active role in medical research.
Vaccine LU AF20513 is the their third Alzheimer's collaboration.
The drug failed to hit its Phase III targets.
Phase-IIIb study results indicate Lyxumia—which is approved abroad but not in the US—was "non-inferior" in terms of controlling blood sugar levels regardless of whether the shot was given before breakfast or later.
The commericalization/development deal covers up to six anti-cancer assets, and gives OncoMed a 50/50 US partnership over the experimental monoclonal antibody demcizumab.
The drugmaker revealed the data a year after stopping a Phase III trial.
The company is rolling out two new clinical trials, and Phase I data suggests an antidote could be on its way.
Early clinical trial results indicate 81% of advanced melanoma patients survived for one year.
New software is helping drugmakers troubleshoot clinical trials before recruitment.
The drugmaker says it will not pursue regulatory review of its Phase III JAK2 inhibitor fedratinib.
The EMA is wading through thousands of comments and may push back its clinical trial transparency initiative.
The company announced the layoffs Friday.
Data released at the Boston meeting of the American Association for the Study of Liver Diseases hints at an upcoming Gilead-Merck brawl.
Researchers think a two-hormone approach could help control diabetes and obesity.